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Abstract
The Juvenile Arthritis Multidimensional Assessment Report (JAMAR) is a new parent/patient-reported outcome measure that 
enables a thorough assessment of the disease status in children with juvenile idiopathic arthritis (JIA). We report the results 
of the cross-cultural adaptation and validation of the parent and patient versions of the JAMAR in the Swedish language. 
The reading comprehension of the questionnaire was tested in 10 JIA parents and patients. Each participating centre was 
asked to collect demographic, clinical data and the JAMAR in 100 consecutive JIA patients or all consecutive patients seen 
in a 6-month period and to administer the JAMAR to 100 healthy children and their parents. The statistical validation phase 
explored descriptive statistics and the psychometric issues of the JAMAR: the 3 Likert assumptions, floor/ceiling effects, 
internal consistency, Cronbach’s alpha, interscale correlations, test–retest reliability and construct validity (convergent and 
discriminant validity). A total of 68 JIA patients (8.8% systemic, 44.1% oligoarticular, 13.2% RF negative polyarthritis, 
33.9% other categories) and 76 healthy children, were enrolled in two centres. The JAMAR components discriminated well 
healthy subjects from JIA patients. All JAMAR components revealed good psychometric performances. In conclusion, the 
Swedish version of the JAMAR is a valid tool for the assessment of children with JIA and is suitable for use both in routine 
clinical practice and clinical research.
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Introduction
The aim of the present study was to cross-culturally adapt 
and validate the Swedish parent, child/adult version of the 
Juvenile Arthritis Multidimensional Assessment Report 
(JAMAR) [1] in patients with juvenile idiopathic arthritis 
(JIA). The JAMAR assesses the most relevant parent/patient-
reported outcomes in JIA, including overall well-being, 
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functional status, health-related quality of life (HRQoL), 
pain, morning stiffness, disease activity/status/course, 
articular and extra-articular involvement, drug-related side 
effects/compliance and satisfaction with illness outcome.
This project was part of a larger multinational study con-
ducted by the Paediatric Rheumatology International Trials 
Organisation (PRINTO) [2] aimed to evaluate the Epide-
miology, Outcome and Treatment of Childhood Arthritis 
(EPOCA) in different geographic areas [3].
We report herein the results of the cross-cultural adapta-
tion and validation of the parent and patient versions of the 
JAMAR in the Swedish language.
Materials and methods
The methodology employed has been described in detail in 
the introductory paper of the supplement [4]. In brief, it was 
a cross-sectional study of JIA children, classified according 
to the ILAR criteria [5, 6] and enrolled from January 2013 
to January 2016. Children were recruited after Ethics Com-
mittee approval and consent from at least one parent.
The JAMAR
The JAMAR [1] includes the following 15 sections:
1. Assessment of physical function (PF) using 15-items 
in which the ability of the child to perform each task is 
scored as follows: 0 = without difficulty, 1 = with some 
difficulty, 2 = with much difficulty, 3 = unable to do and 
not applicable if it was not possible to answer the ques-
tion or the patient was unable to perform the task due to 
their young age or to reasons other than JIA. The total 
PF score ranges from 0 to 45 and has 3 components: 
PF-lower limbs (PF-LL);
PF-hand and wrist (PF-HW) and PF-upper segment (PF-
US) each scoring from 0 to 15 [7]. Higher scores indicating 
higher degree of disability [8–10];
 2. Rating of the intensity of the patient’s pain on a 
21-numbered circle Visual Analogue Scale (VAS) 
[11];
 3. Assessment of the presence of joint pain or swelling 
(present/absent for each joint);
 4. Assessment of morning stiffness (present/absent);
 5. Assessment of extra-articular symptoms (fever and 
rash) (present/absent);
 6. Rating of the level of disease activity on a 21-circle 
VAS;
 7. Rating of disease status at the time of the visit (cat-
egorical scale);
 8. Rating of disease course from previous visit (categori-
cal scale);
 9. Checklist of the medications the patient is taking (list 
of choices);
 10. Checklist of side effects of medications;
 11. Report of difficulties with medication administration 
(list of items);
 12. Report of school/university/work problems caused by 
the disease (list of items);
 13. Assessment of HRQoL, through the Physical Health 
(PhH), and Psychosocial Health (PsH) subscales (5 
items each) and a total score. The four-point Likert 
response, referring to the prior month, are ‘never’ 
(score = 0), ‘sometimes’ (score = 1), ‘most of the time’ 
(score = 2) and ‘all the time’ (score = 3). A ‘not assess-
able’ column was included in the parent version of the 
questionnaire to designate questions that cannot be 
answered because of developmental immaturity. The 
total HRQoL score ranges from 0 to 30, with higher 
scores indicating worse HRQoL. A separate score for 
PhH and PsH (range 0–15) can be calculated [12–14];
 14. Rating of the patient’s overall well-being on a 21-num-
bered circle VAS;
 15. A question about satisfaction with the outcome of the 
illness (Yes/No) [15].
The JAMAR is available in three versions, one for parent 
proxy-report (child’s age 2–18), one for child self-report, 
with the suggested age range of 7–18 years, and one for 
adults.
Cross‑cultural adaptation and validation
The process of cross-cultural adaptation was conducted 
according to international guidelines with 2–3 forward and 
backward translations. In those countries for which the trans-
lation of JAMAR had been already cross-cultural adapted 
in a similar language (i.e. Spanish in South American coun-
tries), only the probe technique was performed. Reading 
comprehension and understanding of the translated ques-
tionnaires were tested in a probe sample of 10 JIA parents 
and 10 patients.
Each participating centre was asked to collect demo-
graphic, clinical data and the JAMAR in 100 consecutive 
JIA patients or all consecutive patients seen in a 6-month 
period and to administer the JAMAR to 100 healthy children 
and their parents.
The statistical validation phase explored the descriptive 
statistics and the psychometric issues [16]. In particular, we 
evaluated the following validity components: the first Likert 
assumption (mean and standard deviation [SD] equivalence); 
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the second Likert assumption or equal items-scale correla-
tions (Pearson r: all items within a scale should contribute 
equally to the total score); third Likert assumption (item 
internal consistency or linearity for which each item of a 
scale should be linearly related to the total score that is 
90% of the items should have Pearson r ≥ 0.4); floor/ceiling 
effects (frequency of items at lower and higher extremes of 
the scales, respectively); internal consistency, measured by 
the Cronbach’s alpha, interscale correlation (the correlation 
between two scales should be lower than their reliability 
coefficients, as measured by Cronbach’s alpha); test–retest 
reliability or intra-class correlation coefficient (reproducibil-
ity of the JAMAR repeated after 1 or 2 weeks); and construct 
validity in its two components: the convergent or external 
validity which examines the correlation of the JAMAR sub-
scales with the 6 JIA core set variables, with the addition 
of the parent assessment of disease activity and pain by the 
Spearman’s correlation coefficients (r) [17] and the discri-
minant validity, which assesses whether the JAMAR dis-
criminates between the different JIA categories and healthy 
children [18].
Quantitative data were reported as medians with 1st and 
3rd quartiles and categorical data as absolute frequencies 
and percentages.
The complete Swedish parent and patient versions of the 
JAMAR are available upon request to PRINTO.
Results
Cross‑cultural adaptation
The Swedish JAMAR was fully cross-culturally adapted 
from the standard English version with 2 forward and 2 
backward translations. The concordance rate between the 
original standard English version of the JAMAR and the 2 
back-translations was 88.6% (109/123 lines) for the parent 
version and 83.3% (100/120 lines) for the child version.
All 123 lines of the parent version of the JAMAR 
were understood by at least 80% of the 10 parents tested 
(median = 100%; range 80–100%). All the 120 lines of the 
patient version of the JAMAR were understood by at least 
80% of the children (median = 100%; range 80–100%). The 
text of the parent JAMAR was unmodified after the probe 
technique.
Demographic and clinical characteristics 
of the subjects
A total of 68 JIA patients and 76 healthy children (total of 
144 subjects), were enrolled at two paediatric rheumatology 
centres.
In the 68 JIA subjects, the JIA categories were 8.8% with 
systemic arthritis, 44.1% with oligoarthritis, 13.2% with RF 
negative polyarthritis, 2.9% with RF positive polyarthritis, 
4.4% with psoriatic arthritis, 11.8% with enthesitis related 
arthritis and 14.8% with undifferentiated arthritis (Table 1).
A total of 142/144 (98.6%) subjects had the parent ver-
sion of the JAMAR completed by a parent (66 from parents 
of JIA patients and 76 from parents of healthy children). 
The JAMAR was completed by 130/142 (91.5%) mothers 
and 12/142 (8.5%) fathers. The child version of the JAMAR 
was completed by 96/144 (66.7%) children age 5.2 years 
or older. Also patients younger than 7-year-old, capable to 
assess their personal condition and able to read and write, 
were asked to fill in the patient version of the questionnaire.
Discriminant validity
The JAMAR results are presented in Table 1, including 
the scores [median (1st–3rd quartile)] obtained for the PF, 
the PhH, the PsH subscales and total score of the HRQoL 
scales. The JAMAR components discriminated well between 
healthy subjects and JIA patients.
In summary, the JAMAR revealed that JIA patients had 
a greater level of disability and pain, as well as a lower 
HRQoL than their healthy peers.
Psychometric issues
The main psychometric properties of both parent and child 
versions of the JAMAR are reported in Table 2. The follow-
ing "results" section refers mainly to the parent’s version 
findings, unless otherwise specified.
Descriptive statistics (first Likert assumption)
There were no missing results for all JAMAR items, since 
data were collected through a web-based system that did not 
allow to skip answers and input of null values. The response 
pattern for both PF and HRQoL was positively skewed 
toward normal functional ability and normal HRQoL. All 
response choices were used for the different HRQoL items 
except for items 1 and 8, whereas a reduced number of 
response choices was used for all the PF items except for 
items 1, 3, 4 and 5.
The mean and SD of the items within a scale were roughly 
equivalent for the PF and for the HRQoL items, except for 
HRQoL items 1 and 8 (data not shown). The median number 
of items marked as not applicable was 0% (0–1%) for the PF 
and 2% (1–4%) for the HRQoL.
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Table 1  Descriptive statistics (medians, 1st 3rd quartiles or absolute frequencies and %) for the 68 JIA patients
Data related to the JAMAR refers to the 66 JIA patients and to the 76 healthy subjects for whom the questionnaire has been completed by the 
parents
JAMAR Juvenile Arthritis Multidimensional Assessment Report, ESR erythrocyte sedimentation rate; MD Medical Doctor, VAS visual analogue 
scale (score 0–10; 0 = no activity, 10 = maximum activity), LOM limitation of motion, ANA Anti-nuclear antibodies, PF physical function (total 
score ranges from 0 to 45), HRQoL Health-Related Quality of Life (total score ranges from 0 to 30), PhH Physical Health (total score ranges 
from 0 to 15), PsH Psychosocial Health (total score ranges from 0 to 15)
p values refer to the comparison of the different JIA categories or to JIA versus healthy. *p < 0.05, **p < 0.001, #p < 0.0001
Systemic Oligoarthritis RF- Poly-
arthritis
RF + Poly-
arthritis
Psoriatic 
Arthritis
Enthesitis 
related 
arthritis
Undifferenti-
ated arthritis
All JIA 
patients
Healthy
N = 6 N = 30 N = 9 N = 2 N = 3 N = 8 N = 10 N = 68 N = 76
Female 2 (33.3%) 24 (80%) 9 (100%) 2 (100%) 2 (66.7%) 3 (37.5%) 6 (60%) 48 (70.6%) 38 (50%)*
Age at visit 13.1 
(6.1–16.3)
10.7 
(7.6–13.3)
13 (7.7–15.7) 15.8 
(15–16.6)
8.7 (8.2–17.5) 14.4 
(7.3–17.3)
13.6 
(8.7–15.5)
12.1 
(7.7–16.2)
9.1 (6.3–
12.7)*
Age at onset 12.8 
(5.7–15.6)
3.7 (2.1–6.7) 8.5 (6.4–12.6) 9.9 (9.5–10.3) 8.5 (4.5–13) 10.6 
(4.6–11.1)
3.6 (2–8.9) 5.5 (2.3–
10.3)*
Disease duration 0.4 (0.4–0.7) 5.3 (3.2–7.6) 2.9 (2.3–4.5) 5.9 (5.5–6.3) 3.8 (0.2–4.6) 3.6 (0.8–6.8) 5.6 (4–12.4) 4.6 (2.2–
6.6)**
ESR 10 (10–10) 8 (4–11) 5 (3.5–9.5) 3 (3–3) 8.5 (5–12) 9 (7–10) 9 (8–10) 8 (4–10)
MD VAS 
(0–10 cm)
0.3 (0–0.5) 1 (0–1.5) 2 (1.5–2) 2.5 (1–4) 1.5 (0.5–2) 1.3 (0.8–3) 1.8 (1–3) 1 (0.5–2)*
No. swollen joints 0 (0–0) 0 (0–1) 1 (0–1) 1.5 (0–3) 0 (0–0) 0 (0–0.5) 0 (0–2) 0 (0–1)
No. joints with 
pain
0 (0–0) 0 (0–1) 1 (0–4) 4 (2–6) 0 (0–0) 0 (0–2.5) 1 (0–7) 0 (0–1.5)
No. joints with 
LOM
0 (0–0) 0 (0–1) 0 (0–0) 2 (0–4) 2 (2–4) 0 (0–1.5) 1.5 (0–4) 0 (0–1.5)*
No. active joints 0 (0–0) 0 (0–1) 1 (0–1) 3 (0–6) 0 (0–0) 0 (0–1) 0.5 (0–2) 0 (0–1)
Active systemic 
features
1 (16.7%) 1 (3.3%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 2 (2.9%)
ANA status 0 (0%) 8 (26.7%) 1 (11.1%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 9 (13.2%)*
Uveitis 0 (0%) 6 (20%) 0 (0%) 0 (0%) 0 (0%) 1 (12.5%) 1 (10%) 8 (11.8%)
PF Total Score 0 (0–2) 1 (0–3) 2 (1–4.5) 12 (11–13) 0 (0–7) 11 (0–12) 5.5 (4–8) 2 (0–6)* 0 (0–0)#
Pain VAS 0.3 (0–1) 1.8 (0–5) 1.8 (0.8–6.3) 6.5 (5–8) 3 (1–4) 5 (1–7.5) 4.5 (3–7) 2.5 (0–5.5) 0 (0–0)#
Disease Activity 
VAS
1 (0–2) 1.5 (0.5–4) 3.3 (1.8–8) 6 (3.5–8.5) 3 (1–3) 2.5 (0–6) 5.3 (3–7) 2.5 (0.5–6)
Well-being VAS 0.8 (0–1.5) 1 (0–5) 3 (1.3–5.8) 4.5 (0–9) 7 (1–8) 2 (0–7) 5 (1.5–5) 1.8 (0–6)
HRQoL PhH 1.5 (1–2) 1 (0–5) 4 (2–9) 9 (9–9) 5 (1–5) 5 (1–9) 7.5 (4–11) 4 (1–7)* 0 (0–0)#
HRQoL PsH 2 (1–3) 1 (0–3) 2.5 (1.5–4.5) 12 (12–12) 8 (0–9) 3 (2–4) 3.5 (1–6) 2 (1–4)* 0 (0–2)#
HRQoL Total 
Score
4 (3–5) 3 (0–8) 6 (4.5–14) 23 (23–23) 13 (1–14) 8 (3–14) 13.5 (6–16) 6 (2–13)* 0 (0–2)#
Pain/swell. in > 1 
joint
1 (16.7%) 15 (50%) 6/8 (75%) 2 (100%) 2 (66.7%) 4/7 (57.1%) 8 (80%) 38 (57.6%)* 0 (0%)#
Morning stiff-
ness > 15 min
1 (16.7%) 10 (33.3%) 3/8 (37.5%) 2 (100%) 0 (0%) 6/7 (85.7%) 8 (80%) 30 (45.5%)* 0 (0%)#
Subjective remis-
sion
1 (16.7%) 15 (50%) 5/8 (62.5%) 2 (100%) 2 (66.7%) 6/7 (85.7%) 9 (90%) 40 (60.6%)*
In treatment 5 (83.3%) 22 (73.3%) 7/8 (87.5%) 1 (50%) 3 (100%) 5/7 (71.4%) 8 (80%) 51 (77.3%)
Reporting side 
effects
2/5 (40%) 7/22 (31.8%) 3/7 (42.9%) 1/1 (100%) 1 (33.3%) 1/5 (20%) 3/8 (37.5%) 18/51 
(35.3%)
Taking medication 
regularly
5/5 (100%) 21/22 (95.5%) 7/7 (100%) 1/1 (100%) 1 (33.3%) 4/5 (80%) 7/8 (87.5%) 46/51 
(90.2%)
With problems 
attending school
1/4 (25%) 4/19 (21.1%) 2/6 (33.3%) 2 (100%) 0 (0%) 2/4 (50%) 7/8 (87.5%) 18/45 (40%)* 0 (0%)#
Satisfied with dis-
ease outcome
5 (83.3%) 25 (83.3%) 5/8 (62.5%) 1 (50%) 1 (33.3%) 6 /7(85.7%) 6 (60%) 49/66 
(74.2%)
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Floor and ceiling effect
The median floor effect was 74.2% (68.2–89.4%) for the 
PF items, 50.0% (42.4–50.0%) for the HRQoL PhH items, 
and 56.1% (42.4–59.1%) for the HRQoL PsH items. The 
median ceiling effect was 0.0% (0–1.5%) for the PF items, 
10.6% (6.1–12.1%) for the HRQoL PhH items, and 3.0% 
(3.0–6.1%) for the HRQoL PsH items. The median floor 
effect was 25.8% for the pain VAS, 19.7% for the disease 
activity VAS and 27.3% for the well-being VAS. The median 
ceiling effect was 0% for the pain VAS, 3.0% for the disease 
activity VAS and 1.5% for the well-being VAS.
Table 2  Main psychometric characteristics between the parent and child version of the JAMAR
JAMAR Juvenile Arthritis Multidimensional Assessment Report, JIA juvenile idiopathic arthritis, VAS Visual Analogue Scale, PF physical func-
tion, HRQoL Health-Related Quality of Life, PhH Physical Health, PsH Psychosocial Health, PF-LL PF-lower limbs, PF-HW PF-hand and 
wrist, PF-US PF-upper segment
Parent N = 66/142 Child N = 47/96
Missing values (1st–3rd quartiles) No missing values No missing values
Response pattern PF and HRQoL positively skewed PF and HRQoL positively skewed
Floor effect, median
 PF 74.2% 74.5%
 HRQoL PhH 50.0% 51.1%
 HRQoL PsH 56.1% 42.6%
 Pain VAS 25.8% 17.0%
 Disease activity VAS 19.7% 17.0%
 Well-being VAS 27.3% 19.1%
Ceiling effect, median
 PF 0.0% 0.0%
 HRQoL PhH 10.6% 8.5%
 HRQoL PsH 3.0% 4.3%
 Pain VAS 0.0% 2.1%
 Disease activity VAS 3.0% 0.0%
 Well-being VAS 1.5% 0.0%
Items with equivalent item-scale correlation 100% for PF, 80% for HRQoL 87% for PF, 90% for HRQoL
Items with items-scale correlation ≥ 0.4 100% for PF, 100% for HRQoL 87% for PF, 100% for HRQoL
Cronbach’s alpha
 PF-LL 0.93 0.91
 PF-HW 0.85 0.82
 PF-US 0.79 0.76
 HRQoL-PhH 0.90 0.89
 HRQoL-PsH 0.87 0.85
Items with item-scale correlation lower than the Cronbach alpha 100% for PF, 100% for HRQoL 100% for PF, 100% for HRQoL
Test–retest intraclass correlation
 PF total score 0.99 0.87
 HRQoL-PhH 0.96 0.96
 HRQoL-PsH 0.91 0.92
Spearman’s correlation with JIA core-set variables, median
 PF 0.5 0.6
 HRQoL PhH 0.7 0.7
 HRQoL PsH 0.5 0.5
 Pain VAS 0.5 0.5
 Disease activity VAS 0.5 0.4
 Well-being VAS 0.5 0.6
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Equal items‑scale correlations (second Likert 
assumption)
Pearson items-scale correlations corrected for overlap 
were roughly equivalent for items within a scale for 100% 
of the PF items and for 80% of the HRQoL items, with the 
exception of items 1 and 5.
Items internal consistency (third Likert assumption)
Pearson items-scale correlations were ≥ 0.4 for 100% of 
items of the PF and 100% of items of the HRQoL.
Cronbach’s alpha internal consistency
Cronbach’s alpha was 0.93 for PF-LL, 0.85 for PF-HW, 0.79 
for PF-US. Cronbach’s alpha was 0.9 for HRQoL-PhH and 
0.87 for HRQoL-PsH.
Interscale correlation
The Pearson correlation of each item of the PF and the 
HRQoL with all items included in the remaining scales of 
the questionnaires was lower than the Cronbach’s alpha.
Test–retest reliability
Reliability was assessed in 7 JIA patients, by re-administer-
ing both versions (parent and child) of the JAMAR after a 
median of 7 days (0–7 days). The intraclass correlation coef-
ficients (ICC) for the PF total score showed an almost per-
fect reproducibility (ICC = 0.99). The ICC for the HRQoL 
PhH and for HRQoL PsH scores showed an almost perfect 
reproducibility (ICC = 0.96 and ICC = 0.91, respectively).
Convergent validity
The Spearman’s correlation of the PF total score with 
the JIA core set of outcome variables ranged from 0.3 to 
0.6 (median = 0.5). The PF total score best correlation 
was observed with the parent assessment of pain (r = 0.7, 
p < 0.001). The correlation of the PF total score with the ESR 
was not significant (p = 0.17). For the HRQoL, the median 
correlation of the PhH with the JIA core set of outcome 
variables ranged from 0.4 to 0.8 (median = 0.7), whereas 
for the PsH ranged from 0.3 to 0.7 (median = 0.5). The PhH 
showed the best correlation with the parent’s assessment of 
pain (r = 0.8, p < 0.001) and the PsH with the parent global 
assessment of well-being (r = 0.7, p < 0.001). The median 
correlations between the pain VAS, the well-being VAS, 
and the disease activity VAS and the physician-centred and 
laboratory measures were 0.5 (0.3–0.7), 0.5 (0.3–0.6), 0.5 
(0.2–0.6), respectively.
Discussion
In this study, the Swedish version of the JAMAR was 
cross-culturally adapted from the original standard Eng-
lish version with 2 forward and 2 backward translations. 
According to the results of the validation analysis, the 
Swedish parent and patient versions of the JAMAR pos-
sess satisfactory psychometric properties. The disease-spe-
cific components of the questionnaire discriminated well 
between patients with JIA and healthy controls. The PF 
total score and HRQoL total score proved to discriminate 
between the different JIA subtypes.
The disease-specific components of the questionnaire 
discriminated well between patients with JIA and healthy 
controls. Psychometric performances were good for all 
domains of the JAMAR and the overall internal consist-
ency was excellent for all the domains.
In the external validity evaluation, the Spearman’s cor-
relations of the PF and HRQoL scores with JIA core set 
parameters ranged from moderate to strong.
The statistical performances of the child version of 
the JAMAR are very similar, although slightly poorer, to 
those obtained for by the parent version, which suggests 
that children are reliable reporters of their disease and 
health status. The JAMAR is aimed to evaluate the side 
effects of medications and school attendance, which are 
other dimensions of daily life that were not previously con-
sidered by other HRQoL tools. This may provide useful 
information for intervention and follow-up in health care.
In conclusion, the Swedish version of the JAMAR was 
found to have satisfactory psychometric properties and it 
is, thus, a reliable and valid tool for the multidimensional 
assessment of children with JIA.
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